arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ELI LILLY & Co

LLY
$1191.45 ▲ +26.26 (+2.25%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

ELI LILLY & Co demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Debt to Equity which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $1.1T
Dividend Yield 0.52%
Revenue Growth 44.7%
Op. Margin
ROIC
FCF / Share $18.74
Trailing P/E 51.8x
Price / Book 40.3x
FCF Yield 1.6%
Debt / Equity 1.54
info Valuation on last close. End-of-day price, Aug 6, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$65.18B
↑ +44.7%
Net Income Profit after all expenses
$20.64B
↑ +94.9%
FCF / Share Free cash flow per share
$18.74
↑ +91.4%
Long-Term Debt Long-term obligations
$40.87B
↑ +38.7%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
91
Returns
99
Financial Health
17
Cash Quality
55

Dividend History

Dividend / share · sourced from SEC filings
$6.23 Latest / share
+15.4% YoY
+14.4% 9-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters